

REMARKS

Pending in the application are claims 2 and 17-36.

In the Office Action of January 17, 2001, the Examiner rejected various claims, including claim 2, under Section 112, *inter alia*, on two principal grounds: (1) the information known by persons skilled in the art regarding the general structure of Complement Factor H proteins, particularly as to the location and identity of the CCP modules; and (2) what other Complement Factor H proteins were known from other species at the priority date.

In their Response dated September 17, 2002, Applicants traversed the Section 112 rejections and amended claim 2. However, in the Office Action dated October 17, 2002, the Examiner indicated that claim 2 was not properly amended.

Claim 2 has now been properly amended. Applicants' Remarks in the Response dated September 17, 2002, apply to the amended claim 2.

Conclusion

Applicants respectfully request entry of the amendment and continued examination of the application. Applicants submit that all claims are now in condition for allowance. The undersigned invites the Examiner to call her to discuss any informalities that remain.

Respectfully submitted,

Date: Nov. 15, 2002

By: Judie D. Dziezak
Judie D. Dziezak, Reg. No. 40,899
Wallenstein & Wagner, Ltd.
311 South Wacker Drive, 53rd Floor
Chicago, Illinois 60606
Phone: (312) 554-3300
Attorneys for Applicants

CERTIFICATE OF MAILING (37 C.F.R. § 1.8a)

I hereby certify that this correspondence is, on the date shown below, being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Box Non-Fee Amendment, Commissioner For Patents, Washington, D.C. 20231 on November 15, 2002.

Kathleen Rundquist
Kathleen Rundquist/161298.1

MARKED-UP CLAIM 2

2. (Amended) A molecule [according to claim 1] comprising complement control protein modules 1-4, 1-5 or 1-6 of complement factor H [, or a molecule resulting from partial modification thereof, or an allelic mutant thereof].